Search for Clinical Trial Results

Sponsored By

Neurofibroma, Plexiform - 25 Studies Found

Status Study
Completed Study Name: R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Condition:
  • Neurofibroma, Plexiform
  • Neurofibromatosis Type I

Date: 2006-06-19
Interventions:
  • Drug: tipifarnib Given orally,
Completed Study Name: Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Condition:
  • Neurofibromatosis 1
  • Neurofibroma, Plexiform

Date: 2004-01-13
Interventions: Drug: Pirfenidone Pirfenidone orally as capsules three times a day approximately every 8 hours for cycle
Active, not recruiting Study Name: Study of PEG-Intron for Plexiform Neurofibromas
Condition: Plexiform Neurofibroma
Date: 2006-11-02
Interventions: Drug: PEG-Intron
Recruiting Study Name: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Date: 2014-06-25
Interventions: Drug: Imatinib Mesylate oral administration Other Na
Terminated Study Name: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Date: 2011-05-27
Interventions: Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg
Completed Study Name: Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Condition:
  • Neurofibromatosis Type I
  • Plexiform Neurofibroma

Date: 2008-07-31
Interventions:
  • Drug: Nexavar (BAY 43-9006) (Sorafenib)
  • Dr
Recruiting Study Name: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Condition:
  • Neurofibromatosis Type 1
  • Plexiform Neurofibroma

Date: 2015-04-02
Interventions:
  • Other: Laboratory Biomarker Analysis

Recruiting Study Name: Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Condition:
  • Neurofibromatosis 1
  • Plexiform Neurofibromas

Date: 2015-09-05
Suspended Study Name: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Condition:
  • Neurofibromatosis
  • NF1
  • Plexiform Neur
    Date: 2011-07-25
    Interventions: Drug: Sutent®/Sunitinib Upon enrollment, subjects will receive Sutent® orally. Adults (Age >
Recruiting Study Name: Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Condition:
  • Neurofibromatosis Type 1
  • Plexiform Neurofibromas

Date: 2015-06-12
Interventions: Other: Acceptance and Commitment Therapy (ACT) Acceptance and Commitment Therapy (ACT), a newer generati
Next >>>